Generic Firms’ Ability To Seek Declaratory Judgment Limited By Federal Circuit
Executive Summary
The Federal Circuit U.S. Court of Appeals has provided further guidance as to when generic companies can seek a declaratory judgment that they do not infringe a patent
You may also be interested in...
Teva Loses Exclusivity For Generic Risperdal; Mylan To Launch Its Product
Mylan is set to become the second generic manufacturer to launch a generic version of the antipsychotic drug Risperdal (risperidone), cutting short Teva's marketing exclusivity
Teva Loses Exclusivity For Generic Risperdal; Mylan To Launch Its Product
Mylan is set to become the second generic manufacturer to launch a generic version of the antipsychotic drug Risperdal (risperidone), cutting short Teva's marketing exclusivity
Declaratory Judgments Win As Federal Circuit Tweaks Standards For ANDA Suits
The parameters under which generic drug firms can seek declaratory judgments against patent holders have been expanded under a ruling by the U.S. Court of Appeals for the Federal Circuit